Molecular Partners Provides Broad Clinical Pipeline Update: MP0712 Data Expected Soon, MP0726 FIH in H2

summarizeSummary

Molecular Partners provided a comprehensive update on its radiotherapeutic pipeline, including anticipated initial data for MP0712, planned first-in-human imaging for MP0726, and new pipeline expansion initiatives.

check_boxKey Events · Product Development and Regulatory · MOLN

• MP0712 Clinical Progress Update

  Dosing is ongoing in the Phase 1/2a trial for MP0712, a DLL3-targeted Radio-DARPin. Initial data is expected within the coming months, with comprehensive efficacy data anticipated in 2027.

• New Compassionate Care Program Initiated

  A DLL3-targeting Radio-DARPin (MP0714) is now being utilized in a compassionate care program in South Africa, highlighting the versatility of DARPins as isotope-agnostic vectors.

• MP0726 First-in-Human Imaging Planned

  First-in-human imaging for MP0726, a Radio-DARPin targeting mesothelin (MSLN), is planned to commence in the second half of 2026.

• Pipeline Expansion and Future INDs

  The company plans to nominate a new radiotherapeutic target in the second half of 2026 and file two Investigational New Drug (IND) applications across its portfolio in 2027.

auto_awesomeAnalysis · MOLN · Life Sciences

This filing provides a significant update on Molecular Partners' core radiotherapeutic pipeline, detailing progress for its lead candidate MP0712, including timelines for initial clinical data. The initiation of a compassionate care program for MP0714 demonstrates the flexibility of their DARPin platform. Furthermore, the advancement of MP0726 to first-in-human imaging and the planned new target nominations and INDs signal a robust and expanding development pipeline, which is critical for a clinical-stage biotech company.